Headquartered in California, Affymax, Inc. (NASDAQ: AFFY) is a
biopharmaceutical company that is engaged in developing novel drugs
to improve the treatment of serious and often life-threatening
conditions. Affymax's product candidate, “Hematide/peginesatide”
has completed Phase 3 clinical trials for the treatment of anemia
associated with chronic renal failure.
Affymax, Inc. was incorporated [more]